Cornelia Lass‐Flörl

39.3k total citations · 8 hit papers
466 papers, 18.8k citations indexed

About

Cornelia Lass‐Flörl is a scholar working on Infectious Diseases, Epidemiology and Cell Biology. According to data from OpenAlex, Cornelia Lass‐Flörl has authored 466 papers receiving a total of 18.8k indexed citations (citations by other indexed papers that have themselves been cited), including 381 papers in Infectious Diseases, 273 papers in Epidemiology and 65 papers in Cell Biology. Recurrent topics in Cornelia Lass‐Flörl's work include Antifungal resistance and susceptibility (346 papers), Fungal Infections and Studies (235 papers) and Plant Pathogens and Fungal Diseases (65 papers). Cornelia Lass‐Flörl is often cited by papers focused on Antifungal resistance and susceptibility (346 papers), Fungal Infections and Studies (235 papers) and Plant Pathogens and Fungal Diseases (65 papers). Cornelia Lass‐Flörl collaborates with scholars based in Austria, Germany and United States. Cornelia Lass‐Flörl's co-authors include Maiken Cavling Arendrup, Manuel Cuenca‐Estrella, Malcolm Richardson, Astrid Mayr, Cornelia Speth, Michaela Lackner, William Hope, Oliver A. Cornely, Susanne Perkhofer and Manfred P. Dierich and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Cornelia Lass‐Flörl

455 papers receiving 18.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

2008 549 citations Maiken Cavling Arendrup, David W. Denning et al. Clinical Microbiology and Infection profile →
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

2011 540 citations Livio Pagano, Andreas H. Groll et al. Clinical Microbiology and Infection profile →
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

2016 432 citations Samir Agrawal, Livio Pagano et al. profile →
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)

2012 384 citations Maiken Cavling Arendrup, Cornelia Lass‐Flörl et al. Clinical Microbiology and Infection profile →
Challenges in the diagnosis and treatment of mucormycosis

2017 329 citations Cornelia Lass‐Flörl et al. profile →
Antifungal drug resistance among Candida species: mechanisms and clinical impact

2015 316 citations Cornelia Lass‐Flörl et al. Mycoses profile →
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

2021 283 citations Martin Hoenigl, Amir Arastehfar et al. profile →
Invasive candidiasis

2024 112 citations Cornelia Lass‐Flörl et al. profile →

Peers

Countries citing papers authored by Cornelia Lass‐Flörl

Since Specialization

Citations

This map shows the geographic impact of Cornelia Lass‐Flörl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cornelia Lass‐Flörl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cornelia Lass‐Flörl more than expected).

Fields of papers citing papers by Cornelia Lass‐Flörl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cornelia Lass‐Flörl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cornelia Lass‐Flörl. The network helps show where Cornelia Lass‐Flörl may publish in the future.

Co-authorship network of co-authors of Cornelia Lass‐Flörl

This figure shows the co-authorship network connecting the top 25 collaborators of Cornelia Lass‐Flörl. A scholar is included among the top collaborators of Cornelia Lass‐Flörl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cornelia Lass‐Flörl. Cornelia Lass‐Flörl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Epidemiological Characteristics and Mortality Predictors of Candidemia Due to Candida albicans: A Single-Center Experience from Türkiye 2025 ·Journal of Fungi ·(unknown), (unknown), İlker Ünal, Tuba Turunç, Cornelia Lass‐Flörl, Macit İlkit	0
2	An update on clinically relevant, rare, and emerging Candida and Saccharomycotina yeasts that have been recently reclassified from Candida 2025 ·Clinical Microbiology Reviews ·Elaine Cristina Francisco, Diego H. Cáceres, (unknown), Guillermo García‐Effrón, Amir Arastehfar, Felipe de Camargo Ribeiro, (unknown), Sarah Santos Gonçalves, João Nóbrega de Almeida, Cornelia Lass‐Flörl, Teun Boekhout, Arnaldo Lopes Colombo	0
3	Is the T2MR Candida Panel a suitable alternative to the SeptiFast for the rapid diagnosis of candidemia in routine clinical practice? 2024 ·Clinical Microbiology and Infection ·(unknown), (unknown), Brigitte Selitsch, (unknown), (unknown), (unknown), Barbara Steinlechner, Johannes Weber, Peter Schellongowski, Christian Zauner, Gürkan Sengölge, Tamara Seitz, Alexander Zoufaly, (unknown), (unknown), Cornelia Lass‐Flörl, Heinz Burgmann, Michael Kundi, Birgit Willinger	5
4	Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual 2024 ·Transplant Infectious Disease ·(unknown), Cornelia Lass‐Flörl, Frédéric Lamoth, Monica A. Slavin, Eloise Williams, Dionysios Neofytos	0
5	Epidemiology of Candidemia in Mashhad, Northeast Iran: A Prospective Multicenter Study (2019–2021) 2024 ·Journal of Fungi ·Somayeh Dolatabadi, Mohammad Javad Najafzadeh, (unknown), Hossein Zarrinfar, Mahsa Jalali, Bram Spruijtenburg, Eelco F. J. Meijer, Jacques F. Meis, Cornelia Lass‐Flörl, Theun de Groot	4
6	Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate 2024 ·Journal of Antimicrobial Chemotherapy ·Johan Maertens, Monica A. Slavin, Martin Hoenigl, George R. Thompson, Malcolm Richardson, Cornelia Lass‐Flörl	2
7	The Austrian landscape of diagnostic capacity and access to treatment for invasive fungal infections 2023 ·Mycoses ·Jon Salmanton‐García, Martin Hoenigl, Helmut J.F. Salzer, Michaela Lackner, Juergen Prattes, Karl Dichtl, (unknown), Robert Krause, Jannik Stemler, Cornelia Lass‐Flörl, Oliver A. Cornely, Birgit Willinger	7
8	Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5 2023 ·Microbiology Spectrum ·Gabriel Diem, Michael Jäger, Stefanie Dichtl, (unknown), Cornelia Lass‐Flörl, Markus Reindl, Doris Wilflingseder, Wilfried Posch	1
9	Influence of Glucose on Candida albicans and the Relevance of the Complement FH-Binding Molecule Hgt1 in a Murine Model of Candidiasis 2022 ·Antibiotics ·(unknown), (unknown), Günter Rambach, (unknown), (unknown), Christian X. Weichenberger, Peter Garred, Silke Huber, Cornelia Lass‐Flörl, Cornelia Speth, Reinhard Würzner	8
10	Interaction in vitro of pulmonary surfactant with antifungal agents used for treatment and prevention of invasive aspergillosis 2021 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), Cornelia Lass‐Flörl, Andreas H. Groll	2
11	Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure 2020 ·Mycoses ·Amir Arastehfar, Farnaz Daneshnia, Mohammadreza Salehi, (unknown), (unknown), Macit İlkit, Weihua Pan, Ferry Hagen, (unknown), Hatice Türk Dağı, Süleyha Hilmioğlu Polat, David S. Perlin, Cornelia Lass‐Flörl	36
12	Immune Parameters for Diagnosis and Treatment Monitoring in Invasive Mold Infection 2019 ·Journal of Fungi ·Jeffrey D. Jenks, Stephen A. Rawlings, Carolina García‐Vidal, Philipp Koehler, Toine Mercier, Juergen Prattes, Cornelia Lass‐Flörl, Marı́a Gómez, Dieter Buchheidt, Livio Pagano, Jean‐Pierre Gangneux, Frank L. van de Veerdonk, Mihai G. Netea, Agostinho Carvalho, Martin Hoenigl	13
13	Diagnostic accuracy of the Aspergillus ‐specific bronchoalveolar lavage lateral‐flow assay in haematological malignancy patients 2015 ·Mycoses ·Juergen Prattes, Michaela Lackner, Susanne Eigl, Frederike Reischies, Reinhard B. Raggam, Christoph Koidl, Holger Flick, (unknown), (unknown), Albert Wölfler, Peter Neumeister, Christopher R. Thornton, Robert Krause, Cornelia Lass‐Flörl, Martin Hoenigl	45
14	Aspergillus-Specific Lateral-Flow Device and Real-Time PCR Testing of Bronchoalveolar Lavage Fluid: a Combination Biomarker Approach for Clinical Diagnosis of Invasive Pulmonary Aspergillosis 2015 ·Journal of Clinical Microbiology ·Gemma Johnson, Shah‐Jalal Sarker, Francesco Nannini, Arianna Ferrini, Emma Taylor, Cornelia Lass‐Flörl, (unknown), Stephen A. Bustin, Samir Agrawal	38
15	Current issues in the clinical management of invasive candida infections – the AGIHO, DMykG, ÖGMM and PEG web‐based survey and expert consensus conference 2009 2011 ·Mycoses ·Meinolf Karthaus, Maria J. G. T. Rüping, Oliver A. Cornely, Angela Steinbach, Andreas H. Groll, Cornelia Lass‐Flörl, Helmut Ostermann, Markus Ruhnke, Jörg Janne Vehreschild	12
16	Environmental Study of Azole-Resistant Aspergillus fumigatus and Other Aspergilli in Austria, Denmark, and Spain 2010 ·Antimicrobial Agents and Chemotherapy ·Klaus Leth Mortensen, Emilia Mellado, Cornelia Lass‐Flörl, Juan L. Rodrı́guez-Tudela, Helle Krogh Johansen, Maiken Cavling Arendrup	194
17	Update: invasive Pilzinfektionen: Diagnose und Therapie in der operativen Intensivmedizin 2010 ·Der Anaesthesist ·Christoph Lichtenstern, Stefanie Swoboda, Markus Hirschburger, Eugen Domann, Torsten Hoppe‐Tichy, (unknown), Cornelia Lass‐Flörl, M. A. Weigand	7
18	In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing 2009 ·Antimicrobial Agents and Chemotherapy ·Susanne Perkhofer, Veronika Lechner, Cornelia Lass‐Flörl	69
19	Clinical performance of FXG: RESP (Asp+) assay for Pneumocystis jirovecii on respiratory specimens 2008 ·Lirias (KU Leuven) ·Philippe M. Hauser, Katrien Lagrou, (unknown), Cornelia Lass‐Flörl, David S. Perlin, (unknown), Johan Maertens, Michael Hughes, Paul Bowyer, David W. Denning, (unknown)	1
20	Helicobacter pylori infection and neopterin 2001 ·Pteridines ·Maximilian Ledochowski, Christian Murr, Cornelia Lass‐Flörl, Dietmar Fuchs	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact